Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemlibra in Mild Hemophilia A
NCT04567511Phase 4Recruiting
- Sponsor
- Indiana Hemophilia and Thrombosis Center
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilia A, sponsored by Indiana Hemophilia and Thrombosis Center. Primary endpoint: Interaction of Hemlibra binding with endogenous altered FVIII protein at Month 13. Started Jul 2022; status: recruiting.
02
Drugs
emicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT04567511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04567511.